Inclusion Criteria:  Females ≥18 and ≤75 years old; Clinical diagnosis with VVC episodes at screening, signs and symptoms score of ≥ 7, with a documented positive potassium hydroxide (KOH) or Gram staining; Subjects of childbearing potential must have a negative pregnancy test result at screening and agree to use highly effective contraceptive measures throughout the study; Willing to sign the informed consent form to participate in this study.  Exclusion Criteria:  Have recurrent vulvovaginal candidiasis (RVVC) as defined by 4 or more confirmed VVC episodes in the past 12 months or history of RVVC; Presence of concomitant vulvovaginitis caused by other pathogens; History of cervical cancer, or "cervical intraepithelial neoplasia or malignancy" or "atypical squamous cells of undetermined significance (ASCUS)" as indicated by Pap test or other tests reported within 1 year before screening; Moderate to severe hepatic and/or renal disorders; Have received systemic or vulvovaginal antifungal drugs, antibacterials, antitrichomonal, CYP3A4 substrates or inducers or inhibitors, or vulvovaginal corticosteroids within 7 days prior to randomization; Have received any estrogen replacement therapy or vaginal topical products within 7 days prior to randomization; Have received systemic corticosteroid therapy within 30 days or systemic immunosuppressant therapy within 90 days prior to randomization; Presence of significant laboratory abnormalities at screening; QTc interval greater than 470 ms or other clinically significant ECG abnormalities at screening; Have planned surgeries or other medical procedures that may impact compliance with the protocol; Known history of hypersensitivity or intolerance to azole antifungal drugs; Being in the menstrual period, pregnant, or lactating at screening, or planning to become pregnant during the study period; History of narcotic or drug abuse or alcoholism within 6 months prior to screening; Have participated in another clinical study and received the investigational drug containing active ingredient within 30 days prior to screening; Other conditions unsuitable for participation in the study per investigator's judgment.